ArticleFrontiers in immunology2025

Two vs three cycles of neoadjuvant immunochemotherapy for resectable non-small-cell lung cancer: a real-world population-based study.

Jiawei Xiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.